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disease. Some studies have reported a reduced risk of 
breast cancer in this group of patients.
Conclusions In conclusion there are several well-charac-
terized health risks in POI women. With every patient, an 
individualized approach is required to properly recognize 
and prevent these risks.
Keywords Premature ovarian insufficiency · 
Cardiovascular disease · Hypoestrogenism · Bone mineral 
density · Sexual dysfunction · Fertility
Introduction
Premature ovarian insufficiency (POI) is defined as an ovar-
ian insufficiency before the age of 40 years [1]. It is charac-
terized by a cessation of menstruation for at least 4 months 
associated with the elevation of serum follicle-stimulating 
hormone (FSH) concentration (FSH >40 IU/l) [2]. Devel-
opment of hypergonadotropic hypogonadism before the 
age of 40 affects approximately 1–2 % of women [3].
Premature ovarian insufficiency can have an influence 
on premature morbidity and mortality [4]. It is related to 
profound hypoestrogenism, which has a deleterious effect 
on different systems in the female body [1]. For the first 
time, this condition was described by Fuller Albright in 
1942 and defined as primary ovarian insufficiency [5].
POI can have a spontaneous or induced background. 
Spontaneous POI is referred to genetic, autoimmunologi-
cal, inflammatory, enzyme deficiency, metabolic, or very 
often idiopathic causes [6, 7]. Induced POI occurs mainly 
due to oncological treatment such as surgery (bilateral 
oophorectomy), chemotherapy and radiotherapy [6]. The 
following factors have been associated with POI: heredity 
factors, ovarian surgery, pelvic surgery, chemotherapy and 
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Results Lack of ovarian steroids synthesis has serious 
consequences for women’s health. The short-term effects 
are similar to spontaneous menopause and refer mainly 
to the climacteric syndrome. In a longer perspective, POI 
affects a variety of aspects. It obviously and drastically 
reduces the chances for spontaneous pregnancies. Oestro-
gen loss leads also to urogenital atrophy. The most com-
mon urogenital symptoms include vaginal dryness, vaginal 
irritation and itching. The urogenital atrophy and hypoes-
trogenism interferes also with sexual functioning. Patients 
with POI are threatened by a decrease in bone mineral 
density (BMD). POI women also experience psychologi-
cal distress and some studies have shown an increased risk 
of neurodegenerating diseases. Overall, POI women have 
a shortened life expectancy, mainly due to cardiovascular 
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radiotherapy, exposure to toxicity and smoking, irregular 
menses in the history [8, 9].
The consequences of POI can be divided into short and 
long-term consequences.
POI short-term consequences mostly result from prompt 
oestrogen deficiency. Short-term consequences may include 
vasomotor symptoms like hot flushes, night sweats, heart pal-
pitations or headaches. The long-term health risks of POI are 
infertility, osteoporosis, cardiovascular and neurologic dis-
eases and an increased risk of premature death [10]. Women 
with the diagnosis of POI also present psychological problems 
including irritability, forgetfulness, insomnia and poor concen-
tration [6]. Moreover, women with POI may present vaginal 
atrophy, which is responsible very often for dyspareunia. The 
aim of this review was to summarize the available scientific 
data regarding POI long-term consequences (Fig. 1).
Fertility, pregnancy, pregnancy outcome
Twenty five percent of POI cases has intermittent and 
unpredictable course, and the chance for spontaneous con-
ception has been estimated to 4–10 % [11, 12]. The ovar-
ian reserve of such women is assessed by an ultrasound 
count of antral follicles and serum anti-mullerian hormone 
(AMH), FSH, estradiol (E2), and inhibin B (InhB) meas-
urements. A cohort of 358 patients with idiopathic POI 
followed up for almost 6 years was described by Bidet 
et al. [12]. The cumulative pregnancy course was 4.3 % at 
48 months. Twenty-one spontaneous pregnancies resulted 
in 16 live births, one twin birth, four miscarriages and one 
elective abortion [12]. Two pregnancies were complicated 
by the occurrence of gestational diabetes mellitus, one 
by hypothyroidism, and one of the singleton pregnancies 
resulted in a preterm birth.
Little progress has been made to improve reproduction 
with patients’ own gametes. There are several studies eval-
uating the effectiveness of oestrogen, Gonadotropin-releas-
ing hormone (GnRH) analogues, glucocorticoids or dana-
zol pretreatment continued with ovarian stimulation with 
gonadotropins. Ovulation is achieved in approximately 
20 % of POI patients. However, pregnancy rates for most 
of the strategies, assessed in systematic review by Robles 
et al. [13], were similar to the spontaneous pregnancy rates 
for these patients.
Oocyte donation is the only proven and recommended 
treatment for women with POI. The pregnancy rate after 
an oocyte donation cycle is around 40 % [14]. Cumulative 
pregnancy rates of oocyte donation treatment are very high 
and after four cycles reach 70–80 % [14]. Ameratunga et al. 
[15] reported following complications in 36 pregnancies 
after oocyte donation in POI patients: three cases of pre-
term labour, five gestational hypertensions, two gestational 
diabetes mellitus and one intrauterine growth retardation 
case. There were two twin gestations after a 2-embryo 
transfer.
There is an overall increase in cancer prevalence fol-
lowed by an increase in long-term survival of the affected 
patients. Protection against iatrogenic POI caused by chem-
otherapy, radiation therapy or surgery assumes a high prior-
ity. Shielding or ovarian transposition during radiotherapy 
and fertility sparing surgery should be considered in young 
females undergoing cancer treatment. GnRH analogue 
given during chemotherapy significantly reduces the risk of 
POI in young cancer patients, but does not exhibit its pro-
tective effects in fertility [16, 17].
Cryopreservation of embryos and mature oocytes is the 
clinically established method, with pregnancy rates and 
livebirths reaching 25 % [18, 19].
All remaining options, such as retrieving immature 
oocytes aiming at maturing them later in vitro, freezing of 
gonadal tissue or novel methods using ovarian stem cells, 
are very promising but still considered experimental.
Urogenital symptoms
Oestrogen loss leads to urogenital atrophy. The most com-
mon urogenital symptoms include vaginal dryness, vaginal 
irritation and itching [20]. The symptoms have been widely 
studied in women undergoing age-appropriate menopausal 
transition. However, there are few studies concerning the 
prevalence and treatment of genitourinary syndrome in POI 
patients. The frequency of most menopausal symptoms in 
the spontaneous POI group is generally lower than in medi-
cally induced premature menopause, with the exception of 
sexual function. It is worsened in more than half of affected 
patients in both groups [21].
Fig. 1  Long-term consequences of premature ovarian insufficiency–
schematic summary
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The study evaluating the vaginal flora and the vaginal 
trophism of 36 women with POI under the age of 40 years, 
using hormonal therapy, found no significant differences 
regarding cytological aspects, pH measurements, vaginal 
microflora types and fungi infection comparing to age-
matched women with normal gonadal function [22]. How-
ever, when sexual function was evaluated in both groups, 
women with POI showed worse sexual performance, with 
more pain and poorer lubrication than women in the control 
group [23]. These findings suggest that hormonal therapy 
in POI patients successfully reestablishes the epithelium 
cells, vaginal pH and microflora, but is not effective enough 
to improve complaints of lubrication and pain.
There are no studies reporting a higher occurrence of 
urinary incontinence among POI patients. Six POI women 
were studied urodynamically before and after the admin-
istration of oral and vaginal oestrogen. Oestrogen supple-
mentation did not produce any significant changes in the 
functional or cystometric parameters. The authors con-
cluded that oestrogen alone is of minimal significance in 
maintaining normal urinary tract physiology in the absence 
of ageing and other factors leading to urinary incontinence 
[24].
Cancer risk
Cancer risk in POI patients is a complex issue. First, ovar-
ian reserve depletion may occur as a result of cytotoxic 
cancer therapy in prepubertal or childbearing age patients 
and there is always concern about the cancer recurrence 
or subsequent neoplasms risk. Next, long-term hormonal 
treatment may carry additional cancer risk in subgroups 
of POI patients. Moreover, there are some epidemiological 
studies suggesting that the early cessation of ovarian func-
tion may be an independent cancer mortality risk factor.
There is no evidence that oestrogen replacement in 
spontaneous POI increases the risk of breast cancer in 
comparison with normally menstruating women [25]. 
Therefore, hormone therapy is recommended until the 
average age of the natural menopause and there is no 
need to start mammographic screening early [2]. It is, 
however, suggested that progestagens with the lower 
potential risk should be preferentially used [12]. Hormo-
nal therapy with oestrogen and progestagens is regarded 
as contraindicated in breast cancer survivors [26]. Ado-
lescent patients experiencing acute ovarian failure after 
cancer treatment will not go through puberty without 
oestrogen treatment [27]. However, in the subsets of 
childhood cancer survivors, such as Hodgkin disease sur-
vivors with the greater risk of breast cancer, heart disease 
and stroke, hormonal therapy implementation should be 
individualized [28].
A large study of middle-age and elderly Chinese women 
demonstrated that POI was inversely associated with 
the incidence of breast cancer [29]. This phenomenon is 
explained by the fact that the cumulative life-exposure of 
women with POI to endogenous circulating sex hormones 
is shorter than that of women with later menopause, leading 
to a reduced risk of breast cancer over a woman’s lifetime. 
Nevertheless, in the same study, POI has been associated 
with an increased risk of cancer mortality, and this increase 
was independent of hormonal replacement therapy [31].
Cardiovascular disease
The main reason for shortened life expectancy in POI 
patients is cardiovascular disease and, therefore, some 
studies have addressed the issue of cardiovascular risk in 
this group of women. To date it has been shown that POI 
women present several risk factors for the development of 
cardiovascular disease: endothelial dysfunction, autonomic 
dysfunction, abnormal lipid profile, insulin action distur-
bances and metabolic syndrome.
Endothelial function, measured as the flow-mediated 
dilation of the brachial artery, has been shown to be sig-
nificantly reduced in POI women. Similarly, the number of 
circulating endothelial progenitor cells number is dimin-
ished and correlated with a decreased serum estradiol con-
centration [30, 31]. The POI women present an increased 
carotid intima media thickness and left ventricular dias-
tolic function [33]. Interestingly, the hormonal therapy of 
6 months duration is able to improve the flow-mediated 
dilation by 2.4-fold, to the same levels as in healthy con-
trols [32]. Goldemeier et al. [32] have also displayed nor-
mal endothelial-dependent vasodilation in POI women 
under hormonal therapy. Despite this, in the same study the 
authors showed impaired baroreflex sensitivity (3.9 ± 1.38 
vs. 7.15 ± 3.62 ms/mmHg) and reduced heart rate varia-
bility (2310 ± 1173 vs. 3754 ± 1921 ms2) of POI women 
(N = 17) in comparison to healthy controls (N = 15) [34].
POI patients present abnormalities in lipid profile, but 
the results are conflicting regarding particular lipoproteins. 
As Knauff et al. [33] have reported, POI women (N = 90) 
show significantly higher TG levels (mean difference: 
0.17 log mmol/L [95 % CI 0.06–0.29]) and lower HDL 
cholesterol levels in comparison to controls (n = 198) after 
correction for age, body mass index and smoking. This dif-
ference has not been confirmed in a smaller study (N = 47 
POI vs. 60 controls) by Gulhan et al. [34]. However, this 
group revealed significantly higher TC and LDL levels in 
POI patients and a significant negative correlation between 
E2 and TC levels (r = −0.291, P = 0.047). Recently, Ates 
et al. [36] reported increased TC and HDL cholesterol in 
POI women (N = 59) vs. healthy controls (N = 59). The 
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analysed population presented similar levels of glucose, 
insulin, HOMA-IR, low-density lipoprotein cholesterol 
(LDL-C), and triglyceride as the controls, but the incidence 
of metabolic syndrome was significantly increased [35]. In 
contrast, other authors detected increased serum glucose, 
insulin and the homeostasis model of assessment-insulin 
resistance (HOMA-IR) in POI women (N = 43) vs. con-
trols (N = 33) [36].
Even though there are conflicting data regarding lipid 
profile and insulin resistance indices, the overall car-
diovascular risk in POI women seems to be significantly 
increased, as the mortality causes analyses in this group 
has shown (above). Especially the risk of mortality from 
ischaemic heart disease is approximately 80 % increased 
in the POI women group compared to women with meno-
pause at 49–55 years [37].
Bone mineral density
An association between oestrogen deficiency in the post-
menopausal period and osteoporosis has been clearly estab-
lished (North American Menopause Society) [38]. Albright 
et al. [39] publications are the first to demonstrate the rela-
tionship between oestrogen deficiency, menopause and an 
increased incidence of fractures in women [41].
However, in young women hypoestrogenism and 
hypoandrogenemia have a deleterious effect on peak bone 
mass (PBM) formation and bone mineral density (BMD) 
status [40]. Lana et al. [41] found that serum FSH concen-
trations, but not oestradiol, are positively associated with 
bone mass loss in skeletal regions (both the spinal column 
and femoral neck) in patients with spontaneous POI.
Numerous studies have revealed a significant decrease 
of BMD in POI patients. Uygur et al. [42] found that both 
the femoral neck bone and spinal bone BMD were signifi-
cantly lower in POI patients than measurements of the con-
trol group.
A large study conducted by Popat [43] including 442 
cases confirmed that POI patients have a lower BMD com-
pared to regularly menstruating women. According to a 
study by Nelson et al. [44] 67 % of patients with POI have 
osteopenia. Leite-Silva et al. [45] studied 50 women with 
POI and found a decrease in the lumbar spine and femoral 
BMD. The lumbar part of the spine was the most affected 
by the BMD decrease. They reported that age generally, 
age of POI and reproductive age were factors associated 
with the BMD of the lumbar spine.
Total body BMD clearly corresponds to the duration of 
ovarian function in POI patients [46].
There are limited data regarding fracture risk in POI 
patients. Clinical studies that compared women experienc-
ing menopause at normal age to women who had premature 
menopause reported relative risks for fracture of approxi-
mately 1.5 in women with premature menopause [47].
Autoimmune and thyroid disease risk
It is estimated that 4–30 % of POI cases are due to auto-
immune aetiology. Therefore, the autoimmune diseases 
risk is increased in this group [48]. According to available 
data, the incidence of autoimmune hypothyroidism, adrenal 
insufficiency, diabetes type 1, hypoparathyroidism and per-
nicious anaemia is increased [49].
Autoimmune thyroiditis seems to be the most common 
autoimmune disease in the POI population. Up to 24 % of 
POI women were reported positive for thyroid peroxidase 
autoantibodies [50]. The overt hypothyroidism is present in 
about 8–20 % of POI individuals [51, 52]. 21-hydroxylase 
adrenal autoantibodies have been reported in 3.2 % of POI 
women. Similarly, approximately 2–3 % of women will 
have asymptomatic autoimmune adrenal insufficiency [52, 
53]. According to another report, women with adrenal auto-
immunity detected by the presence of autoantibodies have a 
50 % risk of developing adrenal insufficiency [53].
The incidence of type 1 diabetes in POI, according to 
available reports, is 2.5 % [54]. The reports about the asso-
ciation of POI with other autoimmune diseases are anecdo-
tal; therefore, these disorders are relatively uncommon.
It has been also shown that non-autoimmune POI can be 
either linked to increased risk of developing autoimmune 
disease. In Nurses Health Study, early menopause (includ-
ing surgical) early menopause (at age <45 years) has been 
related to augmented risk of systemic lupus erythemato-
sus and rheumatoid arthritis [54]. The pathophysiological 
mechanisms related to these phenomena seem to be com-
plex. Probably the immunomodulatory effects of estradiol 
(especially on T helper cells) are of importance, but this 
issue requires further evaluation [55].
Cognitive dysfunction
Work by several groups has provided evidence that early 
menopause can be associated with neurological dysfunc-
tion and an increased risk of dementia. The data suggest 
an increased risk of neurological disorder where POI is 
due to premature menopause or induced from surgery. This 
increased risk appears to be most apparent in the domains 
of global cognitive and verbal memory tests. Where POI 
is caused by genetic disorder, observed cognitive deficien-
cies may be more likely to have a genetic basis rather than 
being due to the effects of sex steroids on the brain. Find-
ings related to the loss of cognitive function after chemo-
therapy or GnRH analogues treatments are mixed.
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Nappi et al. [56] investigated attentive and verbal mem-
ory performances in physiological and surgical menopause, 
drawing attention to the impact of age at menopause. Surgi-
cal menopause affects short-term verbal memory more than 
physiological menopause.
A recent publication of Bove et al. [57] determined the 
association between age at surgical menopause and both 
cognitive decline and Alzheimer’s disease in two longitudi-
nal cohorts. The researchers found that early age at surgical 
menopause was associated with cognitive decline and the 
incidence of Alzheimer’s disease.
In a longitudinal study, Farrag et al. [58] investigated the 
effect of oestrogen deficiency on cognitive function in sur-
gically menopausal women (n = 35). Rapid decline in the 
oestrogen level following surgical menopause was associ-
ated with a deleterious effect on cognitive function.
Another study from the Mayo Clinic Cohort Study of 
Oophorectomy and Ageing, investigated women who had 
both ovaries removed before reaching natural menopause. 
The authors found that examined women experienced a 
long-term increased risk of Parkinsonism, cognitive impair-
ment or dementia, depressive and anxiety symptoms [59].
Phung et al. [60] revealed that premenopausal bilateral 
oophorectomy is associated with a higher risk of dementia, 
suggesting a dose effect of premature oestrogen deficiency 
on dementia. The age-dependent effect suggests that the 
younger brain is more vulnerable to oestrogen deficiency.
Mood and sexual disorders
The psychosocial aspects of POI are most often ignored in 
the context of the diagnosis. The decrease in the mood can 
be caused not only by concerns about their own health, but 
also reproductive problems that occur in younger women 
who want to have children. Being diagnosed with POI can 
be an unexpected and upsetting diagnosis. Women with 
POI experience significant psychologic disturbances, such 
as high levels of depression and low levels of self-esteem, 
with negative effects on sexuality [61]. The diagnosis of 
POI can be an extremely devastating life experience and 
patients often express anger, depression, anxiety, loss and 
sadness. Women after being informed of POI diagnosis can 
be shocked and confused. These words are describing their 
emotional trauma. Some of POI patients report a range of 
emotions and providers should offer support regarding the 
patient’s altered self-image, sexual dysfunction and neuro-
cognitive decline.
Schmitdt et al. [62] evaluated depression in women with 
spontaneous 46, XX primary ovarian insufficiency. The 
researchers compared prevalence of depressive symptoms 
observed in women with primary ovarian insufficiency 
(POI) with women in whom the menopause is normally 
timed. They studied 174 women with spontaneous 46, XX 
POI and 100 women with Turner syndrome. POI proved 
to be associated with an increased lifetime risk for major 
depression. The scientists stressed that more attention 
should be paid to the presence of depression in POI. More-
over, the onset of depression frequently occured after signs 
of altered ovarian function but before the diagnosis of POI.
Fang et al. [63] prospectively compared quality of life 
(QOL) in 75 women at increased risk of ovarian cancer 
who are undergoing risk-reducing salpingo-oophorectomy. 
Women who underwent surgery revealed poorer physi-
cal functioning, greater pain, less vitality, decreased social 
functioning, greater discomfort and less satisfaction with 
sexual activities at 1 month compared to controls. However, 
most QOL deficits observed in the surgical group were no 
longer apparent by the 6-month assessment.
A cross-sectional study comparing sexual function of 58 
POI patients with eumenorrheic women revealed that POI 
patients experienced worse sexual function in relation to 
satisfaction, lubrication, orgasm, pain and arousal. How-
ever, there were no differences between the two groups 
with respect to desire [64]. Similar results showed another 
study including 81 POI patients complaining of less sexual 
arousal, reduced lubrication and increased genital pain, 
without a disturbed feeling of desire comparing to healthy 
controls [65]. The POI patients in this study had decreased 
serum androgen serum levels in comparison to the con-
trol group. Detailed analysis of the hormonal profiles of 
the study group revealed the weak influence of androgen 
on sexual functioning. Higher total testosterone levels 
were associated with an increased frequency of desire, and 
higher androstenedione levels were associated with an ele-
vated frequency of sexual contact [67].
Dennerstein et al. [66] determined the prevalence of 
hypoactive sexual desire disorder (HSDD) among women 
who have undergone surgical menopause with that of pre-
menopausal or naturally menopausal women. The surgi-
cal menopausal women are at an increased risk for HSDD. 
HSDD is associated with diminished sexual and partner 
relationship satisfaction and negative emotional states.
Mortality
Overall mortality is increased in women with POI. Accord-
ing to data from a cohort of 19,731 women from Norway 
found that the menopause before 40 years old was linked to 
an increased mortality rate of 1.06 (CI 0.99–1.14) in com-
parison to women who had menopause at the age 50–52 
[67]. Also early menopause has been shown to reduce the 
life expectancy. Data from a prospective cohort study of 
68,154 US adult women showed that all-cause mortality 
rates were higher among women who reported that their 
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menopause occurred at age 40–44 years compared with 
women who reported that their menopause occurred at age 
50–54 years [rate ratio (RR) = 1.04, 95 % confidence inter-
val (CI) 1.00, 1.08] [68].
The increased risk of all-cause mortality is mainly 
dependent on higher mortality rates from coronary heart 
disease (RR = 1.09, 95 % CI 1.00, 1.18), respiratory dis-
ease (RR = 1.19, 95 % CI 1.02, 1.39), genitourinary dis-
ease (RR = 1.39, 95 % CI 1.07, 1.82) and external causes 
(RR = 1.56, 95 % CI 1.21, 2.02) [69].
Summary: clinical implications
POI patients have an increased risk of certain morbidity 
as well as mortality, as shown above. Recently, the Euro-
pean Society of Human Reproduction published manage-
ment guidelines for POI [69]. According to expert opinion 
women with POI should be advised on how to reduce car-
diovascular risk factors by not smoking, by taking regu-
lar exercise and maintaining a healthy weight to reduce 
the risk of premature death. The cardiovascular evalua-
tion should consist of monitoring annually blood pressure, 
weight and smoking status. As we have stated above, the 
chance for spontaneous pregnancy is very low; therefore, 
oocyte donation is the best option for fertility. The risk of 
BMD decrease and osteoporosis requires proper manage-
ment, i.e. lifestyle interventions, sufficient intake of cal-
cium and vitamin D and hormonal replacement therapy. 
All the patients diagnosed with POI should be evaluated 
for BMD (densitometry). Due to the risk of psychological 
problems, patients should be allowed to obtain psycho-
logical help. Sexual dysfunction should be managed by 
proper counselling, oestrogen replacement and androgen 
supplementation in chosen cases. Vaginal atrophy may by 
improved by the use of topical oestrogens and lubricants. 
According to expert opinion, the neurological well-being 
should be supported by healthy lifestyle interventions and 
oestrogen replacement.
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